This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

53/100

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Long-term cohort studies

Topic: Amyloid, tau and blood-test diagnosis

Introduction We investigated whether cholinesterase inhibitors (ChEIs) benefit cognitive outcomes in mild cognitive impairment due to Alzheimer disease (MCI-AD) and in mild AD dementia (ADdem). Methods Data from 2242 individuals, clinically diagnosed with MCI-AD [Clinical Dementia Rating (CDR), 0 or 0.5] or with mild ADdem (CDR, 0.5 or 1), were available from the National Alzheimer's Coordinating Center's (NACC) Uniform Data Set (UDS). General linear mixed models were used to examine the annual change in the CDR Sum of Boxes (CDR-SB) and in neuropsychological performance.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Han, J. Y., Besser, L. M., Xiong, C., Kukull, W. A., & Morris, J. C. (2019). Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia. Alzheimer disease and associated disorders. https://doi.org/10.1097/wad.0000000000000291

Vancouver

Han JY, Besser LM, Xiong C, Kukull WA, Morris JC. Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia. Alzheimer disease and associated disorders. 2019. doi:10.1097/wad.0000000000000291. PMID: 30633043.

BibTeX

@article{han2019-30633043,
  author  = {Han, J. Y. and Besser, L. M. and Xiong, C. and Kukull, W. A. and Morris, J. C.},
  title   = {{Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia}},
  journal = {Alzheimer disease and associated disorders},
  year    = {2019},
  doi     = {10.1097/wad.0000000000000291},
  pmid    = {30633043},
  url     = {https://doi.org/10.1097/wad.0000000000000291}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Methods Data from 2242 individuals, clinically diagnosed with MCI-AD [Clinical Dementia Rating (CDR), 0 or 0.5] or with mild ADdem (CDR, 0.5 or 1), were available from the National Alzheimer's Coordinating Center's (NACC) Uniform Data Set (UDS).
General linear mixed models were used to examine the annual change in the CDR Sum of Boxes (CDR-SB) and in neuropsychological performance.
We compared slopes before and after ChEI initiation among ChEI users, and also compared the change in scores of ChEI users versus nonusers.
Results Thirty-four percent of 944 MCI-AD and 72% of 1298 ADdem participants were ChEI users.

Why it matters

This study examined whether cholinesterase inhibitor drugs improve thinking in people with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia. The findings suggest these drugs may not provide benefit in these milder stages, which is important for guiding treatment decisions.

Study details

Participants2,242
Effect sizeor 0.5
Evidence strengthLow

How this study scored 53/100

Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer disease and associated disorders)
Journal's citation record	1 / 4	Alzheimer Disease & Associated Disorders: journal h-index 131 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	2 / 5	2019 — within 10 year(s) of the newest study here
Sample size	3 / 4	2,242 participants
Effect reported	2 / 3	Effect reported as a number, without an interval or test
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	4 / 7	Cited 66 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	7.3 citations a year over 9 year(s) since 2019
Impact for its field and year	3 / 6	Cited 5.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	2 / 6	Cited by 4 other studies in this library
Still being cited	2 / 4	Cited 26 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	4 / 4	Last-listed author John C. Morris: h-index 209 (OpenAlex, whole career)
Institution's track record	3 / 3	University of Washington: institution h-index 3,540 (OpenAlex)
Multicenter collaboration	2 / 3	OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 30633043)
Free to read	0 / 2	Behind a paywall — scores zero
Total	53 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.

Later studies that cite this one

4 studies in the alzhub library list this one in their references.

Related studies in Long-term cohort studies

Also tagged “placebo-controlled”

783 studies in the library carry the topic tag “placebo-controlled”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Long-term cohort studies

See all studies in Long-term cohort studies →